Hepatitis C virus-induced cryoglobulinemia

Kidney International

Volumn 76, Issue 8, 2009, Pages 818-824

  Charles, Edgar D ^a,b   Dustin, Lynn B ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

B cells; Cryoglobulinemia; HCV; Lymphoma; Rheumatoid factor; Vasculitis

Indexed keywords

CRYOGLOBULIN; IMMUNOGLOBULIN G; PEGINTERFERON; PREDNISONE; RHEUMATOID FACTOR; RIBAVIRIN; RITUXIMAB; VIRUS RNA;

ANTIGEN ANTIBODY COMPLEX; B CELL LYMPHOMA; B LYMPHOCYTE; CRYOGLOBULINEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPHENOTYPING; PRIORITY JOURNAL; SHORT SURVEY; VASCULITIS;

ANTIVIRAL AGENTS; B-LYMPHOCYTES; CRYOGLOBULINEMIA; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHATIC DISEASES; PLASMAPHERESIS; TREATMENT OUTCOME;

EID: 70349658771     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.247     Document Type: Short Survey

References (83)

1. Meltzer M, Franklin EC, Elias K et al. Cryoglobulinemia - a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40: 837-856.
2. Brouet JC, Clauvel JP, Danon F et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974; 57: 775-788.
3. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495.
4. Ferri C, Sebastiani M, Giuggioli D et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355-374.
5. Dammacco F, Sansonno D, Piccoli C et al. The cryoglobulins: an overview. Eur J Clin Invest 2001; 31: 628-638.
6. Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 1997; 19: 111-129.
7. Pawlotsky JM, Ben Yahia M, Andre C et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841-848.
8. Cicardi M, Cesana B, Del Ninno E et al. Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. J Viral Hepat 2000; 7: 138-143.
9. Gorevic PD. Cryopathies: cryoglobulins and cryofibrinogenimia. In: Frank MM, Austen KF, Claman HN (eds). Samter's Immunologic Diseases, 5 edn, vol.2. Little, Brown and Company: Boston, 1995, p 951.
10. Bichard P, Ounanian A, Girard M et al. High prevalence of hepatitis C virus RNA in the supernatant and the cryoprecipitate of patients with essential and secondary type II mixed cryoglobulinemia. J Hepatol 1994; 21: 58-63.
11. Lunel F, Musset L, Cacoub P et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106: 1291-1300.
12. Adinolfi LE, Utili R, Attanasio V et al. Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study. Ital J Gastroenterol 1996; 28: 1-9.
13. Kayali Z, Buckwold VE, Zimmerman B et al. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 2002; 36: 978-985.
14. Cacoub P, Poynard T, Ghillani P et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42: 2204-2212.
15. Giordano TP, Henderson L, Landgren O et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007; 297: 2010-2017.
16. Congia M, Clemente MG, Dessi C et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 1996; 24: 1338-1341.
17. Amoroso A, Berrino M, Canale L et al. Are HLA class II and immunoglobulin constant region genes involved in the pathogenesis of mixed cryoglobulinemia type II after hepatitis C virus infection? J Hepatol 1998; 29: 36-44.
18. De Re V, Caggiari L, De Vita S et al. Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. Dig Liver Dis 2007; 39(Suppl 1): S65-S71.
19. Lenzi M, Frisoni M, Mantovani V et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 1998; 91: 2062-2066.
20. Sebastiani GD, Bellisai F, Caudai C et al. Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients. J Biol Regul Homeost Agents 2005; 19: 17-22.
21. Hwang SJ, Chu CW, Huang DF et al. Genetic predispositions for the presence of cryoglobulinemia and serum autoantibodies in Chinese patients with chronic hepatitis C. Tissue Antigens 2002; 59: 31-37.
22. Nagasaka A, Takahashi T, Sasaki T et al. Cryoglobulinemia in Japanese patients with chronic hepatitis C virus infection: host genetic and virological study. J Med Virol 2001; 65: 52-57.
23. Saadoun D, Landau DA, Calabrese LH et al. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 2007; 46: 1234-1242.
24. Johnson RJ, Gretch DR, Yamabe H et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-470.
25. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54: 650-671.
26. Authier FJ, Pawlotsky JM, Viard JP et al. High incidence of hepatitis C virus infection in patients with cryoglobulinemic neuropathy. Ann Neurol 1993; 34: 749-750.
27. Matsuo K, Kusano A, Sugumar A et al. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004; 95: 745-752.
28. De Vita S, De Re V, Gasparotto D et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000; 43: 94-102.
29. Ferri C, Caracciolo F, Zignego AL et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 392-394.
30. Zuckerman E, Zuckerman T, Levine AM et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997; 127: 423-428.
31. Talamini R, Montella M, Crovatto M et al. Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 2004; 110: 380-385.
32. De Vita S, Sacco C, Sansonno D et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 1997; 90: 776-782.
33. Hermine O, Lefrere F, Bronowicki JP et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
34. Zuckerman E, Zuckerman T, Sahar D et al. bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol 2001; 112: 364-369.
35. Zignego AL, Ferri C, Giannelli F et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137: 571-580.
36. Libra M, Gloghini A, Malaponte G et al. Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol 2008; 49: 170-174.
37. Limpens J, Stad R, Vos C et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85: 2528-2536.
38. Libra M, De Re V, De Vita S et al. Low frequency of bcl-2 rearrangement in HCV-associated non-Hodgkin's lymphoma tissue. Leukemia 2003; 17: 1433-1436.
39. Franzin F, Efremov DG, Pozzato G et al. Clonal B-cell expansions in peripheral blood of HCV-infected patients. Br J Haematol 1995; 90: 548-552.
40. Sansonno D, De Vita S, Iacobelli AR et al. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998; 160: 3594-3601.
41. Charles ED, Green RM, Marukian S et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 2008; 111: 1344-1356.
42. Carbonari M, Caprini E, Tedesco T et al. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol 2005; 174: 6532-6539.
43. Ivanovski M, Silvestri F, Pozzato G et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998; 91: 2433-2442.
44. Chan CH, Hadlock KG, Foung SK et al. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 2001; 97: 1023-1026.
45. Toubi E, Gordon S, Kessel A et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006; 27: 134-139.
46. Fabris M, Quartuccio L, Sacco S et al. B-Lymphocyte stimulator (BLyS) upregulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford) 2007; 46: 37-43.
47. Sene D, Limal N, Ghillani-Dalbin P et al. Hepatitis C virus-associated B-cell proliferation - the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford) 2007; 46: 65-69.
48. Landau DA, Rosenzwajg M, Saadoun D et al. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. Ann Rheum Dis 2009; 68: 337-344.
49. Giannini C, Gragnani L, Piluso A et al. Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? Blood 2008; 112: 4353-4354.
50. Sung VM, Shimodaira S, Doughty AL et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 2003; 77: 2134-2146.
51. Zignego AL, Ferri C, Giannini C et al. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol 1997; 142: 545-555.
52. Takyar ST, Li D, Wang Y et al. Specific detection of minus-strand hepatitis C virus RNA by reverse-transcription polymerase chain reaction on PolyA(+)-purified RNA. Hepatology 2000; 32: 382-387.
53. Sansonno D, Lauletta G, Montrone M et al. Virological analysis and phenotypic characterization of peripheral blood lymphocytes of hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol 2006; 143: 288-296.
54. Lerat H, Berby F, Trabaud MA et al. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest 1996; 97: 845-851.
55. De Vita S, De Re V, Sansonno D et al. Lack of HCV infection in malignant cells refutes the hypothesis of a direct transforming action of the virus in the pathogenesis of HCV-associated B-cell NHLs. Tumori 2002; 88: 400-406.
56. Marukian S, Jones CT, Andrus L et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 2008; 48: 1843-1850.
57. Maillard P, Lavergne JP, Siberil S et al. Fcgamma receptor-like activity of hepatitis C virus core protein. J Biol Chem 2004; 279: 2430-2437.
58. Majumder M, Ghosh AK, Steele R et al. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53- dependent manner. J Virol 2001; 75: 1401-1407.
59. Rosa D, Saletti G, De Gregorio E et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005; 102: 18544-18549.
60. Machida K, Cheng KT, Pavio N et al. Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol 2005; 79: 8079-8089.
61. Quinn ER, Chan CH, Hadlock KG et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001; 98: 3745-3749.
62. Keck ZY, Xia J, Cai Z et al. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 2007; 81: 1043-1047.
63. Machida K, Kondo Y, Huang J et al. HCV-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol 2008; 82: 6711-6720.
64. De Re V, Sansonno D, Simula MP et al. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia 2006; 20: 1145-1154.
65. Levine JW, Gota C, Fessler BJ et al. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005; 32: 1164-1167.
66. Landau DA, Saadoun D, Halfon P et al. Relapse of hepatitis C virusassociated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008; 58: 604-611.
67. Ferri C, Marzo E, Longombardo G et al. Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trial. Gut 1993; 34: S144-S145.
68. Misiani R, Bellavita P, Fenili D et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-756.
69. Casato M, Agnello V, Pucillo LP et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90: 3865-3873.
70. Cresta P, Musset L, Cacoub P et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 1999; 45: 122-128.
71. Mazzaro C, Franzin F, Tulissi P et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996; 77: 2604-2613.
72. Vallisa D, Bernuzzi P, Arcaini L et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23: 468-473.
73. Carriero D, Fabrizi F, Uriel AJ et al. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008; 31: 295-302.
74. Ahmed MS, Wong CF. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? J Nephrol 2007; 20: 350-356.
75. Glennie MJ, French RR, Cragg MS et al. Mechanisms of killing by anti- CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-3837.
76. Cacoub P, Delluc A, Saadoun D et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008; 67: 283-287.
77. Saadoun D, Rosenzwajg M, Landau D et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008; 111: 5334-5341.
78. Sansonno D, De Re V, Lauletta G et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101: 3818-3826.
79. Lake-Bakaar G, Dustin L, McKeating J et al. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 2007; 109: 845-846.
80. Koziolek MJ, Scheel A, Bramlage C et al. Effective treatment of hepatitis Cassociated immune-complex nephritis with cryoprecipitate apheresis and antiviral therapy. Clin Nephrol 2007; 67: 245-249.
81. Murai H, Inaba S, Kira J et al. Hepatitis C virus associated cryoglobulinemic neuropathy successfully treated with plasma exchange. Artif Organs 1995; 19: 334-338.
82. Stefanutti C, Di Giacomo S, Mareri M et al. Immunoadsorption apheresis (Selesorb) in the treatment of chronic hepatitis C virus-related type 2 mixed cryoglobulinemia. Transfus Apher Sci 2003; 28: 207-214.
83. Vila AT, Barnadas MA, Ballarin J et al. Cutaneous ulcers with type I cryoglobulinemia treated with plasmapheresis. Eur J Dermatol 2004; 14: 186-189.